Vita Coco Company, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vita Coco Company, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $222.60M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $198.78M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $180.73M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $103.36M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $113.15M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $104.86M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $92.99M | Mar 14, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.32M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $55.95M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $46.63M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $7.81M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $19.02M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $32.66M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $9.42M | Mar 14, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.53M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $73.82M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $56.49M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $3.06M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $24.59M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $46.86M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $13.37M | Mar 14, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $399.0K | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $398.0K | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $418.0K | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $541.0K | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $477.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $313.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $642.0K | Mar 14, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.06M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $124.96M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $124.24M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $100.31M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $88.56M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $74.40M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $78.92M | Mar 14, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.17M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $42.90M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $107.16M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | ($10.94M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($16.17M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $33.32M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $21.77M | Mar 14, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.15M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $974.0K | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $599.0K | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $982.0K | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $557.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $392.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $1.01M | Mar 14, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $461.16M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $362.38M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $285.68M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $197.76M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $197.48M | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | $183.86M | Mar 14, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.62M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $103.56M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $83.25M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $56.66M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $74.31M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $81.56M | Mar 14, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $331.54M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $258.82M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $202.44M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $141.09M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $123.17M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $102.22M | Mar 14, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.79M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $7.79M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $7.79M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $7.79M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $7.79M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $7.79M | Mar 14, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.01M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $156.69M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $100.74M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $55.18M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $47.37M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $28.35M | Mar 14, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.87M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $164.67M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $132.54M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $19.63M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $28.69M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $72.18M | Mar 14, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 14, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 14, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.08M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 56.96M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 56.90M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 56.02M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 55.56M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 58.19M | Mar 14, 2022 |